Qualit-E-SpeakPharma-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diamyd

            Therapeutic Area: Endocrinology

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Protein Sciences Corporation

            Deal Size: $5.0 million Upfront Cash: $5.0 million

            Deal Type: Agreement February 05, 2020

            Details:

            The agreement facilitates the transition of the manufacturing process of recombinant GAD65, to a new manufacturer for future anticipated commercial manufacture.